As the essential regulators of organ fibrosis, macrophages undergo marked phenotypic and
functional changes after organ injury. These changes in macrophage phenotype and …

The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …

Background Cardiovascular diseases kill approximately 17 million people globally every
year, and they mainly exhibit as myocardial infarctions and heart failures. Heart failure (HF) …

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …

In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …

Obesity continues to be a public health problem in the general population, and also
significantly increases the risk for the development of new-onset heart failure (HF). However …

Aims The lack of effective therapies for patients with heart failure with preserved ejection
fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to …

The majority of older patients who develop heart failure (HF), particularly older women, have
a preserved left ventricular ejection fraction (HFpEF). Patients with HFpEF have severe …

Cardiovascular disease (CVD) is one of the most common causes of death that kills
approximately 17 million people annually. The main reasons behind CVD are myocardial …

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity with
complex pathophysiology and manifestations. Phenomap** is the process of applying …